On March 24, 2026, PMGC Holdings Inc. announced that its wholly owned subsidiary, Northstrive Biosciences Inc., has entered into a Third Amendment to its License Agreement with MOA Life Plus Co., Ltd. This amendment updates the achievement of certain milestones related to pre-clinical trials and Investigational New Drug Applications. The agreement originally dated April 30, 2024, has been modified to include new timelines for these milestones. As part of the agreement, PMGC Holdings will pay MOA a monetary value as consideration for entering into this amendment within 30 days of execution. This development is expected to enhance PMGC's operational capabilities in the biopharmaceutical sector, particularly in advancing its product pipeline. The company is optimistic that these changes will facilitate a more efficient path towards regulatory approvals and market entry for its products, potentially leading to increased revenue streams in the future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.